NO329997B1 - Anvendelse av TA1 for fremstilling av et farmasoytisk preparat for behandling eller forebygging av en Aspergillus-infeksjon i et pattedyr. - Google Patents
Anvendelse av TA1 for fremstilling av et farmasoytisk preparat for behandling eller forebygging av en Aspergillus-infeksjon i et pattedyr. Download PDFInfo
- Publication number
- NO329997B1 NO329997B1 NO20054912A NO20054912A NO329997B1 NO 329997 B1 NO329997 B1 NO 329997B1 NO 20054912 A NO20054912 A NO 20054912A NO 20054912 A NO20054912 A NO 20054912A NO 329997 B1 NO329997 B1 NO 329997B1
- Authority
- NO
- Norway
- Prior art keywords
- tai
- pharmaceutical preparation
- mammal
- cells
- dcs
- Prior art date
Links
- 201000002909 Aspergillosis Diseases 0.000 title claims description 13
- 208000036641 Aspergillus infections Diseases 0.000 title claims description 13
- 241000124008 Mammalia Species 0.000 title claims description 13
- 238000002360 preparation method Methods 0.000 title claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108010078233 Thymalfasin Proteins 0.000 claims abstract description 53
- 102400000800 Thymosin alpha-1 Human genes 0.000 claims abstract description 53
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims abstract description 53
- 229960004231 thymalfasin Drugs 0.000 claims abstract description 53
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 40
- 206010061598 Immunodeficiency Diseases 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 29
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 19
- 230000000843 anti-fungal effect Effects 0.000 claims description 14
- 201000009085 invasive aspergillosis Diseases 0.000 claims description 14
- 229940121375 antifungal agent Drugs 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 8
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 6
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 6
- 229960003942 amphotericin b Drugs 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 4
- 108010046075 Thymosin Proteins 0.000 claims description 3
- 102000007501 Thymosin Human genes 0.000 claims description 3
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims description 3
- 239000003429 antifungal agent Substances 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 241000228212 Aspergillus Species 0.000 abstract description 16
- 208000015181 infectious disease Diseases 0.000 abstract description 16
- 238000010322 bone marrow transplantation Methods 0.000 abstract description 15
- 238000000034 method Methods 0.000 abstract description 4
- 230000003213 activating effect Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 26
- 102000002689 Toll-like receptor Human genes 0.000 description 20
- 108020000411 Toll-like receptor Proteins 0.000 description 20
- 210000004072 lung Anatomy 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 15
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 13
- 108010065805 Interleukin-12 Proteins 0.000 description 12
- 102000013462 Interleukin-12 Human genes 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 230000011664 signaling Effects 0.000 description 11
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 10
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 10
- 230000002538 fungal effect Effects 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 210000000440 neutrophil Anatomy 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 9
- 102000006992 Interferon-alpha Human genes 0.000 description 8
- 108010047761 Interferon-alpha Proteins 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000002950 deficient Effects 0.000 description 7
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 7
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 7
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 7
- 241000233866 Fungi Species 0.000 description 6
- 102000003814 Interleukin-10 Human genes 0.000 description 6
- 108090000174 Interleukin-10 Proteins 0.000 description 6
- 108090001007 Interleukin-8 Proteins 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 108010057466 NF-kappa B Proteins 0.000 description 5
- 102000003945 NF-kappa B Human genes 0.000 description 5
- 206010057249 Phagocytosis Diseases 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 230000008782 phagocytosis Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 4
- 108091054455 MAP kinase family Proteins 0.000 description 4
- 229920000392 Zymosan Polymers 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000031261 interleukin-10 production Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 210000005174 lung dendritic cell Anatomy 0.000 description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 3
- 102000043131 MHC class II family Human genes 0.000 description 3
- 108091054438 MHC class II family Proteins 0.000 description 3
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 3
- 210000000447 Th1 cell Anatomy 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229960002442 glucosamine Drugs 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000004957 immunoregulator effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000005007 innate immune system Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 208000004235 neutropenia Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 210000005006 adaptive immune system Anatomy 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000021995 interleukin-8 production Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000007898 magnetic cell sorting Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000005937 nuclear translocation Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- STMRGLKPBJVVEG-UHFFFAOYSA-N 2-(2-oxopropyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CC(=O)C)C(=O)C2=C1 STMRGLKPBJVVEG-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000758250 Aspergillus fumigatus A1163 Species 0.000 description 1
- 108010021800 B7-2 Antigen Proteins 0.000 description 1
- 102000007697 B7-2 Antigen Human genes 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010063916 CD40 Antigens Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010068051 Chimerism Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 description 1
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 description 1
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 1
- 101000777452 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 11 Proteins 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000800479 Homo sapiens Toll-like receptor 9 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 102000046418 human ADAM11 Human genes 0.000 description 1
- 102000045718 human TLR2 Human genes 0.000 description 1
- 102000045717 human TLR4 Human genes 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000008975 immunomodulatory function Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 229950000038 interferon alfa Drugs 0.000 description 1
- 230000011488 interferon-alpha production Effects 0.000 description 1
- 230000019734 interleukin-12 production Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 102000005309 phosducin Human genes 0.000 description 1
- 108010031256 phosducin Proteins 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000020884 susceptibility to aspergillosis Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45791103P | 2003-03-28 | 2003-03-28 | |
PCT/US2004/009550 WO2004087067A2 (fr) | 2003-03-28 | 2004-03-29 | Traitement d'infections par aspergillus a l'aide de thymosine alpha 1 |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20054912D0 NO20054912D0 (no) | 2005-10-24 |
NO20054912L NO20054912L (no) | 2005-12-20 |
NO329997B1 true NO329997B1 (no) | 2011-02-07 |
Family
ID=42828702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20054912A NO329997B1 (no) | 2003-03-28 | 2005-10-24 | Anvendelse av TA1 for fremstilling av et farmasoytisk preparat for behandling eller forebygging av en Aspergillus-infeksjon i et pattedyr. |
Country Status (17)
Country | Link |
---|---|
US (2) | US8207294B2 (fr) |
EP (1) | EP1613340B1 (fr) |
JP (1) | JP4629033B2 (fr) |
KR (1) | KR101089145B1 (fr) |
AT (1) | ATE467422T1 (fr) |
AU (1) | AU2004226403B2 (fr) |
BR (1) | BRPI0408892A (fr) |
CA (1) | CA2520400C (fr) |
DK (1) | DK1613340T3 (fr) |
EA (1) | EA008037B1 (fr) |
IL (1) | IL171118A (fr) |
MX (1) | MXPA05010391A (fr) |
NO (1) | NO329997B1 (fr) |
NZ (1) | NZ542900A (fr) |
PL (1) | PL1613340T3 (fr) |
UA (1) | UA80870C2 (fr) |
WO (1) | WO2004087067A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE467422T1 (de) | 2003-03-28 | 2010-05-15 | Sciclone Pharmaceuticals Inc | Behandlung von aspergillus-infektionen mit thymosin alpha 1 |
CN101072582B (zh) * | 2004-12-06 | 2012-06-27 | 赛生制药有限公司 | 作为癌症疫苗佐剂的α胸腺肽 |
CN101448519B (zh) * | 2006-05-19 | 2012-02-15 | 希格马托制药工业公司 | 胸腺素α1在免疫疾病治疗中的用途 |
ITRM20060583A1 (it) * | 2006-10-27 | 2008-04-28 | Francesco Bistoni | Uso della timosina alfa 1 per la preparazione di un medicamento per la prevenzione e la cura delle allergie |
EP2675272A4 (fr) * | 2011-02-09 | 2015-03-11 | Sciclone Pharmaceuticals Inc | Peptide de type thymosine alpha servant à prévenir et traiter l'infection, et à en atténuer la gravité |
ITUB20153714A1 (it) * | 2015-09-18 | 2017-03-18 | Luigina Romani | Timosina alfa 1 per l?uso nel trattamento della fibrosi cistica. |
AU2016217473B2 (en) | 2015-02-09 | 2021-07-29 | Sci Clone Pharmaceuticals International (Sg) Pte. Ltd. | Thymosin alpha 1 for use in treatment of cystic fibrosis |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4002740A (en) | 1975-08-21 | 1977-01-11 | Gideon Goldstein | Tridecapeptide compositions and methods |
US4079127A (en) | 1976-10-28 | 1978-03-14 | Board Of Regents Of The University Of Texas | Thymosin alpha 1 |
US4116951A (en) | 1977-04-22 | 1978-09-26 | Hoffmann-La Roche Inc. | [Asn2 ]-thymosin α1 and analogs thereof |
DE2919592A1 (de) | 1979-05-15 | 1981-01-15 | Max Planck Gesellschaft | Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon |
US4612365A (en) | 1980-03-25 | 1986-09-16 | Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften | Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments |
US4374197A (en) | 1980-10-30 | 1983-02-15 | Hoffmann-La Rocche Inc. | Process for thymosin α1 |
TW224053B (fr) | 1991-09-13 | 1994-05-21 | Paul B Chretien | |
CN1058500C (zh) | 1993-02-03 | 2000-11-15 | 施塞克龙药品公司 | 胸腺素α-1衍生物 |
CN1072961C (zh) | 1993-03-05 | 2001-10-17 | 施塞克龙药品公司 | 治疗对干扰素治疗无反应者的丙型肝炎的方法 |
TW252045B (fr) * | 1993-10-07 | 1995-07-21 | Allan L Goldstein | |
RU2107692C1 (ru) * | 1995-06-07 | 1998-03-27 | Дейгин Владислав Исакович | Пептид и способ его получения |
US5888980A (en) | 1994-06-30 | 1999-03-30 | Bio-Logic Research And Development Corporation | Compositions for enhancing immune function |
US5632983A (en) | 1994-11-17 | 1997-05-27 | University Of South Florida | Method for treating secondary immunodeficiency |
WO1998035696A1 (fr) * | 1997-02-18 | 1998-08-20 | Sciclone Pharmaceuticals, Inc. | Utilisation de thymosine alpha 1 pour la fabrication d'un medicament destine a favoriser le developpement de cellules souches |
UA80957C2 (en) * | 2001-11-01 | 2007-11-26 | Sciclone Pharmaceuticals Inc | Method of administering a thymosin alpha 1 peptide |
ATE467422T1 (de) | 2003-03-28 | 2010-05-15 | Sciclone Pharmaceuticals Inc | Behandlung von aspergillus-infektionen mit thymosin alpha 1 |
-
2004
- 2004-03-29 AT AT04749495T patent/ATE467422T1/de active
- 2004-03-29 CA CA2520400A patent/CA2520400C/fr not_active Expired - Lifetime
- 2004-03-29 BR BRPI0408892-1A patent/BRPI0408892A/pt not_active IP Right Cessation
- 2004-03-29 KR KR1020057018335A patent/KR101089145B1/ko not_active IP Right Cessation
- 2004-03-29 NZ NZ542900A patent/NZ542900A/en not_active IP Right Cessation
- 2004-03-29 UA UAA200509921A patent/UA80870C2/xx unknown
- 2004-03-29 PL PL04749495T patent/PL1613340T3/pl unknown
- 2004-03-29 WO PCT/US2004/009550 patent/WO2004087067A2/fr active Application Filing
- 2004-03-29 US US10/551,341 patent/US8207294B2/en active Active
- 2004-03-29 JP JP2006509423A patent/JP4629033B2/ja not_active Expired - Lifetime
- 2004-03-29 DK DK04749495.0T patent/DK1613340T3/da active
- 2004-03-29 EA EA200501414A patent/EA008037B1/ru not_active IP Right Cessation
- 2004-03-29 EP EP04749495A patent/EP1613340B1/fr not_active Expired - Lifetime
- 2004-03-29 AU AU2004226403A patent/AU2004226403B2/en not_active Ceased
- 2004-03-29 MX MXPA05010391A patent/MXPA05010391A/es active IP Right Grant
-
2005
- 2005-09-27 IL IL171118A patent/IL171118A/en not_active IP Right Cessation
- 2005-10-24 NO NO20054912A patent/NO329997B1/no not_active IP Right Cessation
-
2012
- 2012-05-29 US US13/482,978 patent/US8389680B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
MXPA05010391A (es) | 2005-11-04 |
US8207294B2 (en) | 2012-06-26 |
EA200501414A1 (ru) | 2006-04-28 |
EP1613340A4 (fr) | 2009-07-01 |
DK1613340T3 (da) | 2010-08-30 |
US20120295840A1 (en) | 2012-11-22 |
CA2520400C (fr) | 2013-02-19 |
WO2004087067A2 (fr) | 2004-10-14 |
EP1613340B1 (fr) | 2010-05-12 |
IL171118A (en) | 2011-10-31 |
WO2004087067A3 (fr) | 2004-12-29 |
UA80870C2 (en) | 2007-11-12 |
EA008037B1 (ru) | 2007-02-27 |
AU2004226403A1 (en) | 2004-10-14 |
JP2006521406A (ja) | 2006-09-21 |
US20070129292A1 (en) | 2007-06-07 |
JP4629033B2 (ja) | 2011-02-09 |
KR20050114264A (ko) | 2005-12-05 |
KR101089145B1 (ko) | 2011-12-02 |
NZ542900A (en) | 2007-06-29 |
AU2004226403B2 (en) | 2008-12-04 |
NO20054912D0 (no) | 2005-10-24 |
CA2520400A1 (fr) | 2004-10-14 |
NO20054912L (no) | 2005-12-20 |
EP1613340A2 (fr) | 2006-01-11 |
US8389680B2 (en) | 2013-03-05 |
PL1613340T3 (pl) | 2010-10-29 |
ATE467422T1 (de) | 2010-05-15 |
BRPI0408892A (pt) | 2006-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Romani et al. | Thymosin α 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling | |
US8389680B2 (en) | Treatment of Aspergillus infections with alpha thymosin peptides | |
Actor et al. | Lactoferrin as a natural immune modulator | |
US20210244789A1 (en) | Compositions and methods for treatment of intracellular damage and bacterial infection | |
JP7033066B2 (ja) | 免疫寛容応答を生成する組成物及び方法 | |
RU2461390C2 (ru) | Иммунологически активные составы | |
Meng et al. | Synergistic effect of methionine encephalin (MENK) combined with pidotimod (PTD) on the maturation of murine dendritic cells (DCs) | |
US20110294736A1 (en) | Compounds and methods for the treatment of autoimmune and inflammatory disease | |
CN101426813B (zh) | 具有免疫调节和抗肿瘤能力的肽 | |
Rosenkranz et al. | 10. Immunobiology and Hematology of Zinc | |
WO2015200469A1 (fr) | Manf en tant que régulateur du fonctionnement du système immunitaire | |
ES2345552T3 (es) | Tratamiento de infecciones por aspergillus con timosina alfa 1. | |
WO2016046419A1 (fr) | Nouveaux composés immunostimulants | |
Yawe | Macrophages Are Regulators of Whole Body Metabolism: A Dissertation | |
Lu | Acyloxyacyl Hydrolase: Studies on Its Regulation and Function in Mus Musculus | |
US20070041937A1 (en) | G-csf derivative for inducing immunological tolerance | |
Johnston et al. | Enhanced Tumor Metastasis in Response to |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |